γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs

Blood

Volumn 120, Issue 26, 2012, Pages 5153-5162

  Gründer, Cordula ^a   Van Dorp, Suzanne ^a   Hol, Samantha ^a   Drent, Esther ^a   Straetemans, Trudy ^a   Heijhuurs, Sabine ^a   Scholten, Kirsten ^a   Scheper, Wouter ^a   Sebestyen, Zsolt ^a   Martens, Anton ^a   Strong, Roland ^b   Kuball, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA9DELTA2 T CELL RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; GAMMA9DELTA2 T LYMPHOCYTE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84871499910     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-432427     Document Type: Article

References (45)

1. Gomes AQ, Martins DS, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 2010;70(24):10024-10027.
2. Marcu-Malina V, van DS, Kuball J. Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert Opin Biol Ther. 2009;9(5):579-591.
3. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
4. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy. 2008;10(8):775-783.
5. Castella B, Vitale C, Coscia M, Massaia M. Vgamma9Vdelta2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci. 2011;68(14):2419-2432.
6. Nedellec S, Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: from signals to functions. Semin Immunol. 2010;22(4):199-206.
7. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107.
8. Nicol AJ, Tokuyama H, Mattarollo SR, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer. 2011;105(6):778-786.
9. Marcu-Malina V, Heijhuurs S, van BM, et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gammadelta T-cell receptor. Blood. 2011;118(1):50-59.
10. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De LG. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163-168. (Pubitemid 36152311)
11. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67(1):5-8. (Pubitemid 46142752)
12. Allison TJ, Winter CC, Fournie JJ, Bonneville M, Garboczi DN. Structure of a human gammadelta T-cell antigen receptor. Nature. 2001;411(6839):820-824. (Pubitemid 32588108)
13. Morita CT, Lee HK, Wang H, Li H, Mariuzza RA, Tanaka Y. Structural features of nonpeptide prenyl pyrophosphates that determine their antigenicity for human gamma delta T cells. J Immunol. 2001;167(1):36-41. (Pubitemid 32567758)
14. Wang H, Fang Z, Morita CT. Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs. J Immunol. 2010;184(11):6209- 6222.
15. Lefranc MP. IMGT, the international ImMuno-GeneTics database. Nucleic Acids Res. 2003;31(1):307-310.
16. Bukowski JF, Morita CT, Band H, Brenner MB. Crucial role of TCR gamma chain junctional region in prenyl pyrophosphate antigen recognition by gamma delta T cells. J Immunol. 1998;161(1):286-293. (Pubitemid 28285534)
17. Miyagawa F, Tanaka Y, Yamashita S, et al. Essential contribution of germline-encoded lysine residues in Jgamma1.2 segment to the recognition of nonpeptide antigens by human gammadelta T cells. J Immunol. 2001;167(12):6773- 6779. (Pubitemid 33144167)
18. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77(1):51-59. (Pubitemid 19125653)
19. Miyazaki K. MEGAWHOP cloning: a method of creating random mutagenesis libraries via megaprimer PCR of whole plasmids. Methods Enzymol. 2011;498:399-406.
20. Kuball J, Hauptrock B, Malina V, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med. 2009;206(2):463-475.
21. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128(2):189-201. (Pubitemid 20120262)
22. Kuball J, Theobald M, Ferreira EA, et al. Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation. 2004;78(12):1774-1779. (Pubitemid 40041644)
23. van Dorp S, Resemann H, et al. The immunological phenotype of rituximab-sensitive chronic GVHD: a phase II study. Haematologica. 2011;96(9):1380-1384.
24. Huber C, Bobek N, Kuball J, et al. Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell Death Differ. 2005;12(4):317-325. (Pubitemid 40520683)
25. Besold K, Frankenberg N, Pepperl-Klindworth S, et al. Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol. 2007;88(Pt 5):1429-1439. (Pubitemid 46723223)
26. Kuball J, Schuler M, Antunes FE, et al. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 2002;9(13):833-843. (Pubitemid 34716327)
27. Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol. 2008;140(3):303-312.
28. Battistini L, Borsellino G, Sawicki G, et al. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol. 1997;159(8):3723-3730. (Pubitemid 127469626)
29. Moris A, Rothenfusser S, Meuer E, Hangretinger R, Fisch P. Role of gammadelta T cells in tumor immunity and their control by NK receptors. Microbes Infect. 1999;1(3):227-234.
30. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol. 2005;175(4):2144-2151. (Pubitemid 41113819)
31. Voss RH, Kuball J, Theobald M. Designing TCR for Cancer Immunotherapy. Methods Mol Med. 2005;109:229-256.
32. Corvaisier M, Moreau-Aubry A, Diez E, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol. 2005;175(8):5481-5488. (Pubitemid 41456435)
33. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother. 2007;56(8):1285-1297. (Pubitemid 46763941)
34. Xu C, Zhang H, Hu H, et al. Gammadelta T cells recognize tumor cells via CDR3delta region. Mol Immunol. 2007;44(4):302-310. (Pubitemid 44308356)
35. Born WK, Zhang L, Nakayama M, et al. Peptide antigens for gamma/delta T cells. Cell Mol Life Sci. 2011;68(14):2335-2343.
36. Sandstrom A, Scharf L, McRae G, Hawk AJ, Meredith SC, Adams EJ. gammadelta T cell receptors recognize the nonclassical major histocompatibility complex (MHC) molecule T22 via conserved anchor residues in a MHC-peptide-like fashion. J Biol Chem. 2012;287(8):6035-6043.
37. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature. 2002;418(6897):552-556. (Pubitemid 34851403)
38. Urban EM, Chapoval AI, Pauza CD. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin Dev Immunol. 2010;2010:732893.
39. Evans PS, Enders PJ, Yin C, Ruckwardt TJ, Malkovsky M, Pauza CD. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology. 2001;104(1):19-27.
40. Harly C, Guillaume Y, Nedellec S, et al. Key implication of CD277/Butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T cell subset. Blood. 2012;120(11):2269-2279.
41. Ribot JC, debarros A, Silva-Santos B. Searching for "signal 2": costimulation requirements of gammadelta T cells. Cell Mol Life Sci. 2011;68(14):2345-2355.
42. Willcox CR, Pitard V, Netzer S, et al. Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor. Nat Immunol. 2012;13(9):872-879.
43. Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity. 2001;15(1):83-93. (Pubitemid 32728322)
44. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102(1):200-206. (Pubitemid 36759655)
45. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A. 2000;97(10):5387-5392. (Pubitemid 30313728)